BioDrugs (B) is a scholarly journal dedicated to publishing research in the field of Pharmacology, Toxicology and Pharmaceutics. Springer is the publisher of this esteemed journal. The P-ISSN assigned to BioDrugs is 1173-8804 and its abbreviated form is BioDrugs.
BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease. The Journal includes: - Definitive reviews on topics relating to the development and use of biotechnology in healthcare and the management of disease. - Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement. - Original research articles on the clinical development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products. - Leading/Current Opinion articles providing an overview of contentious or emerging issues and key regulatory and ethical issues. - Adis Drug Evaluations reviewing the properties and place in therapy of biotechnology-based drugs. - Adis Biosimilar Briefs summarizing key characteristics and clinical use of biosimilar drugs.
|Pharmacology, Toxicology and Pharmaceutics
BioDrugs Abbreviation : ISO Journal abbreviation refers to the shortened form or acronym used to represent the full title of a scholarly journal. The ISO4 Abbreviation of BioDrugs Journal is BioDrugs.
The Ranking of BioDrugs in 2024 is 1812. Ranking systems aim to provide an indication of a journal's quality, influence, and prestige within a specific field or discipline.
The Impact Factor of BioDrugs in 2024 is 6.4. it is all calculated by Clarivate, which means how many times a particular citation has been published in the past two years.
The SCImago of BioDrugs in 2024 is 1.646. It is measured by the number of citations which are made by the particular journals, and the journal from where the citations arrived from.
The H-Index of BioDrugs in 2024 is 76. The H-index is calculated on how many times a particular author is cited and the number of published papers that a particular author has.
The Quartile of BioDrugs is Q1. A quartile has three points, which are the upper quartile, median, and lower quartile. The main motive of the quartile is to calculate the interquartile range, that resembles the changes across the median.
The BioDrugs is indexed in (Indexing details)
|Web of Science
Indexing services aim to make it easier for researchers, scholars, and readers to discover and access articles from various journals within a specific field or discipline.
The Editor-in-chief of BioDrugs is Kathy Fraser
BioDrugs Processing/Submission Fee : Article submission/Processing fees (APC), also known as manuscript Publication fees or processing fees (APC), are charged by journals to authors for submitting/publishing their research papers/article.
The APC/Submission (Publication) Fee of BioDrugs is £3490.0, $4990.00, €3990.00
BioDrugs Call for paper : BioDrugs invites original research contributions for consideration of publication in BioDrugs journal.
Journal seeking submissions in the broad areas of Pharmacology, Toxicology and Pharmaceutics that align with journal's focus on Pharmacology, Toxicology and Pharmaceutics.
for details about call for paper please visit to the official website of the journal to check the details about call for papers.
Publishing in BioDrugs involves the following steps:
Yes, the BioDrugs journal is indexed in PubMed.
Yes, the BioDrugs journal is indexed in Scopus.
Yes, the BioDrugs journal is indexed in UGC.
No, the BioDrugs journal is not indexed in Index copernicus.
No, BioDrugs journal is not a predatory journal.
The Impact Factor of the BioDrugs is 6.4.
The Ranking of the BioDrugs is 1812.
Yes the BioDrugs (B) journal is a peer-reviewed journal.
Yes the BioDrugs journal is a peer-reviewed journal and good to publish your paper.
Yes, BioDrugs is a open access (Hybrid) journal.